Lyka Labs Limited (LYKALABS.NS)

INR 110.34

(-0.31%)

Long Term Debt Summary of Lyka Labs Limited

Lyka Labs Limited's latest annual long term debt in 2023 was 429.06 Million INR , down -34.86% from previous year.
Lyka Labs Limited's latest quarterly long term debt in 2024 Q1 was - INR , down -100.0% from previous quarter.
Lyka Labs Limited reported annual long term debt of 658.69 Million INR in 2022, up 6.74% from previous year.
Lyka Labs Limited reported annual long term debt of 617.08 Million INR in 2021, down -59.29% from previous year.
Lyka Labs Limited reported quarterly long term debt of 462.67 Million INR for 2023 Q2, down 0.0% from previous quarter.
Lyka Labs Limited reported quarterly long term debt of - INR for 2023 Q1, down -100.0% from previous quarter.

Annual Long Term Debt Chart of Lyka Labs Limited (2023 - 2009)

Historical Annual Long Term Debt of Lyka Labs Limited (2023 - 2009)

Year	Long Term Debt	Long Term Debt Growth
2023	429.06 Million INR	-34.86%
2022	658.69 Million INR	6.74%
2021	617.08 Million INR	-59.29%
2020	1.51 Billion INR	19.19%
2019	1.27 Billion INR	62.24%
2018	783.89 Million INR	1829.77%
2017	40.62 Million INR	-88.49%
2016	352.93 Million INR	40.59%
2015	251.04 Million INR	-13.2%
2014	289.21 Million INR	-50.14%
2013	580.01 Million INR	-13.72%
2012	672.21 Million INR	-47.17%
2011	1.27 Billion INR	11.87%
2010	1.13 Billion INR	4.49%
2009	1.08 Billion INR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- INR	-100.0%
2023 Q2	462.67 Million INR	0.0%
2023 Q1	- INR	-100.0%
2023 FY	429.06 Million INR	-34.86%
2023 Q4	429.06 Million INR	0.0%
2023 Q3	- INR	-100.0%
2022 Q3	- INR	-100.0%
2022 Q2	1.1 Billion INR	0.0%
2022 Q1	- INR	-100.0%
2022 FY	658.69 Million INR	6.74%
2022 Q4	658.69 Million INR	0.0%
2021 FY	617.08 Million INR	-59.29%
2021 Q2	454.96 Million INR	0.0%
2021 Q3	- INR	-100.0%
2021 Q1	- INR	-100.0%
2021 Q4	617.08 Million INR	0.0%
2020 Q4	1.51 Billion INR	0.0%
2020 Q3	- INR	-100.0%
2020 Q2	1.35 Billion INR	0.0%
2020 Q1	- INR	-100.0%
2020 FY	1.51 Billion INR	19.19%
2019 Q4	1.27 Billion INR	0.0%
2019 FY	1.27 Billion INR	62.24%
2019 Q3	- INR	-100.0%
2019 Q2	792.79 Million INR	0.0%
2019 Q1	- INR	-100.0%
2018 Q1	- INR	0.0%
2018 FY	783.89 Million INR	1829.77%
2018 Q4	783.89 Million INR	0.0%
2017 FY	40.62 Million INR	-88.49%
2016 Q4	352.93 Million INR	0.0%
2016 Q1	- INR	-100.0%
2016 Q2	293.31 Million INR	0.0%
2016 FY	352.93 Million INR	40.59%
2016 Q3	- INR	-100.0%
2015 FY	251.04 Million INR	-13.2%
2015 Q2	290.23 Million INR	0.0%
2015 Q4	253.14 Million INR	-12.78%
2015 Q1	- INR	-100.0%
2015 Q3	290.23 Million INR	0.0%
2014 Q4	289.21 Million INR	0.0%
2014 Q1	514.39 Million INR	0.0%
2014 FY	289.21 Million INR	-50.14%
2013 Q3	- INR	-100.0%
2013 Q1	672.21 Million INR	0.0%
2013 FY	580.01 Million INR	-13.72%
2013 Q2	775.25 Million INR	15.33%
2012 Q4	672.21 Million INR	0.0%
2012 FY	672.21 Million INR	-47.17%
2012 Q3	- INR	-100.0%
2012 Q2	603.5 Million INR	0.0%
2011 FY	1.27 Billion INR	11.87%
2010 FY	1.13 Billion INR	4.49%
2009 FY	1.08 Billion INR	0.0%

Peer Long Term Debt Comparison of Lyka Labs Limited

Name	Long Term Debt	Long Term Debt Difference
Biocon Limited	129.32 Billion INR	99.668%
Blue Jet Healthcare Limited	3.79 Million INR	-11221.029%
Concord Biotech Limited	18.87 Million INR	-2173.805%
Dishman Carbogen Amcis Limited	2.45 Billion INR	82.531%
Jubilant Ingrevia Limited	4.25 Billion INR	89.918%
Panacea Biotec Limited	209.9 Million INR	-104.415%
Piramal Pharma Limited	24.83 Billion INR	98.273%
SMS Lifesciences India Limited	331.45 Million INR	-29.452%
Supriya Lifescience Limited	50.2 Million INR	-754.715%
Syngene International Limited	1 Billion INR	57.093%
TAKE Solutions Limited	7.5 Million INR	-5620.893%
Zota Health Care Limited	631.64 Million INR	32.071%